

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2019**

**Commission File Number: 001-38281**

---

**ERYTECH Pharma S.A.**  
(Translation of registrant's name into English)

---

**Bâtiment Adénine, 60 Avenue Rockefeller  
69008 Lyon France**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

ERYTECH Pharma S.A. (the “Company”) is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of June 30, 2018 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

## EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
99.1	Unaudited Interim Condensed Consolidated Statements of Financial Position as of December 31, 2017 and June 30, 2018
99.2	Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the Six Months Ended June 30, 2017 and 2018

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **ERYTECH Pharma S.A.**

Date: January 4, 2019

By: /s/ Eric Soyer

Name Eric Soyer

Title: Chief Financial Officer and Chief Operating Officer



## UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

*(Amounts in thousands of euros, except per share amounts)*

	Six Months Ended June 30,	
	2018	2017
	€	€
<b>Operating income</b>		
Revenues		
Other income	2,265	1,788
<b>Total operating income</b>	<b>2,265</b>	<b>1,788</b>
<b>Operating expenses</b>		
Research and development	(16,752)	(12,082)
General and administrative	(7,393)	(3,895)
<b>Total operating expenses</b>	<b>(24,145)</b>	<b>(15,977)</b>
<b>Operating loss</b>	<b>(21,880)</b>	<b>(14,189)</b>
Financial income	2,966	160
Financial expenses	(42)	(47)
<b>Financial income</b>	<b>2,924</b>	<b>114</b>
Income tax	(14)	(5)
<b>Net loss</b>	<b>(18,970)</b>	<b>(14,081)</b>
<b>Basic / diluted loss per share (€/share)</b>	<b>(1.06)</b>	<b>(1.42)</b>